Literature DB >> 18827985

Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker.

Chris G Parsons1, Kate Gilling.   

Abstract

Electrophysiological techniques can be used to great effect to help determine the mechanism of action of a compound. However, many factors can compromise the resulting data and their analysis, such as the speed of solution exchange, expression of additional ion channel populations including other ligand-gated receptors and voltage-gated channels, compounds having multiple binding sites, and current desensitization and rundown. In this chapter, such problems and their solutions are discussed and illustrated using data from experiments involving the uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine. Memantine differs from many other NMDA receptor channel blockers in that it is well tolerated and does not cause psychotomimetic effects at therapeutic doses. Various electrophysiological parameters of NMDA-induced current blockade by memantine have been proposed to be important in determining therapeutic tolerability, potency, onset and offset kinetics, and voltage dependency. These were all measured using whole cell patch-clamp techniques using hippocampal neurons. Full results are shown here for memantine, and these are summarized and compared with those from similar experiments with other NMDA channel blockers. The interpretation of these results is discussed, as are theories concerning the tolerability of NMDA channel blockers, with the aim of illustrating how electrophysiological data can be used to form and support a physiological hypothesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18827985     DOI: 10.1007/978-1-59745-529-9_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

Review 1.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

2.  Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors.

Authors:  Jamie A Abbott; Gabriela K Popescu
Journal:  Mol Pharmacol       Date:  2020-06-29       Impact factor: 4.436

3.  Extremely low frequency magnetic field induces human neuronal differentiation through NMDA receptor activation.

Authors:  Alp Özgün; Ana Marote; Leo A Behie; António Salgado; Bora Garipcan
Journal:  J Neural Transm (Vienna)       Date:  2019-07-17       Impact factor: 3.575

Review 4.  Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

Authors:  Timothy J Revett; Glen B Baker; Jack Jhamandas; Satyabrata Kar
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

5.  In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons.

Authors:  Viktor Szegedi; Gábor Juhász; Chris G Parsons; Dénes Budai
Journal:  J Neural Transm (Vienna)       Date:  2010-09-07       Impact factor: 3.575

6.  Structural insights into binding of therapeutic channel blockers in NMDA receptors.

Authors:  Tsung-Han Chou; Max Epstein; Kevin Michalski; Eve Fine; Philip C Biggin; Hiro Furukawa
Journal:  Nat Struct Mol Biol       Date:  2022-05-30       Impact factor: 18.361

7.  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Authors:  Andreea L Turcu; Júlia Companys-Alemany; Matthew B Phillips; Dhilon S Patel; Christian Griñán-Ferré; M Isabel Loza; José M Brea; Belén Pérez; David Soto; Francesc X Sureda; Maria G Kurnikova; Jon W Johnson; Mercè Pallàs; Santiago Vázquez
Journal:  Eur J Med Chem       Date:  2022-04-08       Impact factor: 7.088

8.  Open-label memantine in fragile X syndrome.

Authors:  Craig A Erickson; Jennifer E Mullett; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2009-07-16

9.  NMDA Receptors in Glial Cells: Pending Questions.

Authors:  David Dzamba; Pavel Honsa; Miroslava Anderova
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.